Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of glofitamab alone or with R-ICE after obinutuzumab pretreatment in pediatric and young adult relapsed/refractory mature B-cell non-Hodgkin lymphoma
CTR20252960Phase 2Active
- Sponsor
- Roche
- Start
- Jul 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in mature B-cell lymphoma, Burkitt lymphoma (BL), B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Roche. Started Jul 2025; status: active.
02
Drugs
glofitamab
03
Conditions
mature B-cell lymphomaBurkitt lymphoma (BL)B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on CTR20252960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252960.